CAR T-Cell Therapy

 

Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T cells for treatment of leukemia and lymphoma.  There is now rapid growth in research on the therapeutic uses of CAR T cells.

A therapeutic CAR (chimeric antigen receptor) is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signaling domains derived from the TCR g chain, along with other costimulatory receptors.  The scFv provides a specific binding domain that recognizes target proteins on cancer cells.  A patient’s own T cells are isolated and activated, then transfected with a gene expressing the CAR.  This reprograms the T cells to identify and attack tumor cells expressing the target protein, creating personalized immune cells designed to specifically target the patient’s cancer.

 The first FDA approved treatments were CAR T cells directed against the B cell protein CD19.  Success with CD19 has inspired new research identifying additional targets for several blood cancers and even solid tumors.  For example, early clinical trials using CAR-T treatment  suggest BCMA and CD22 are promising targets for multiple myeloma and acute lymphoblastic leukemia.  CD19-targeting CAR T cells are also in development as co-therapies with therapeutic antibodies targeting the PD-1:PD-L1 and CD28:CTLA4 pathways.  The aim of these early studies is to determine if CAR T cells can overcome the challenges of adaptive resistance to immune checkpoint therapies.

 At BPS Bioscience, we strive to provide tools at the cutting edge of cancer research. We produce a growing list of experimental cell lines, recombinant proteins, and screening services to advance the search for new CAR T cell therapies.  Contact us to find out how we can help with your research needs.

Items 1 to 25 of 55 total

per page
Page:
  1. 1
  2. 2
  3. 3

Catalog#SizeProduct NamePrice
100173

50 µg
100 µg

Anti-BCMA Antibody (Single-Chain Variable Fragment), His-Tag
Starting at:
$335
79667 96 reactions BAFF:BCMA[Biotinylated] Inhibitor Screening Assay Kit
$765
79724 2 vials BCMA / Luciferase - CHO Recombinant Cell Line
$8,800
79500 2 vials BCMA CHO Recombinant Cell Line (High, Medium, or Low Expression)
Starting at:
$6,000
79467 50 μg BCMA, Fc-fusion (IgG1), Avi-Tag, Biotin-Labeled HiP™
$435
79465 100 µg BCMA, Fc-Fusion, Avi-Tag HiP™
$320
79722 96 Reactions BCMA:APRIL[Biotinylated] Inhibitor Screening Assay Kit
$765
71101 100 µg Carbonic Anhydrase 9 (CA9), His-tag
$480
79640 2 Vials CD123 (IL3Ra) - CHO Recombinant Cell Line (High, Medium, or Low Expression)
Starting at:
$6,000
100058 100 µg CD123, Fc-Fusion (IgG1) Avi-Tag
$320
100068 50 µg CD123, Fc-Fusion (IgG1) Avi-Tag, Biotin-Labeled
$435
79714 2 vials CD19 / Firefly Luciferase - CHO Recombinant Cell Line
$8,800
79561 2 vials CD19 CHO Recombinant Cell Line (Low, Medium and High Expression)
Starting at:
$6,000
79472 100 μg CD19, Fc-Fusion (IgG1), Avi-Tag
$320
79475 50 μg CD19, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled
$435
79624 2 Vials CD20 CHO Recombinant Cell Line (High or Medium Expression)
Starting at:
$6,000
79715 2 vials CD22 / Luciferase - CHO Recombinant Cell Line
$8,800
79557 2 vial CD22 CHO Recombinant Cell Line (Medium and High Expression)
Starting at:
$6,000
79464 100 μg CD22, Fc-fusion, Avi-Tag HiP™
$325
79466 50 μg CD22, Fc-fusion, Avi-Tag, Biotin-labeled HiP™
$435
100073 100 µg CD277, Fc-Fusion (IgG1) Avi-Tag
$320
72511 50 μg CD30, Fc-Fusion (IgG1), Avi-Tag, Biotin-Labeled
$435
79607 2 Vials CD37 CHO Recombinant Cell Line(High, Medium, or Low Expression)
Starting at:
$6,000
79615 2 Vials CD38 CHO Recombinant Cell Line (High, Medium or Low Expression)
Starting at:
$6,000
71277 100 μg CD38, His-Tag (Human), HiP™
$325

Items 1 to 25 of 55 total

per page
Page:
  1. 1
  2. 2
  3. 3